The National Institute of Allergy and Infectious Diseases awarded a $168,078.40 firm fixed-price purchase order to 10X Genomics, Inc. on June 28, 2021, designated as a Total Small Business set-aside. This contract represents an administrative de-obligation of unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), with an ultimate completion date of June 28, 2022. 10X Genomics, headquartered in Pleasanton, California, is a leading biotechnology company specializing in advanced genomic analysis platforms, reagents, and bioinformatics software for single-cell and spatial transcriptomics research. The award aligns with NIAID's mission to support cutting-edge research in infectious diseases and immunology through provision of specialized molecular analysis tools.
This award reflects 10X Genomics' established role as a primary federal supplier of genomic research equipment and consumables across the National Institutes of Health system. The company maintains substantial existing contract relationships with NIAID and other NIH institutes, including a $7 million indefinite delivery contract with the National Institute on Aging and a $750,000 indefinite delivery contract with the National Institute of Neurological Disorders and Stroke. The company's products—including Chromium systems, Xenium analyzers, and associated reagent kits—are critical to federal research institutions investigating complex biological systems and disease mechanisms. No major subcontractors were identified in this award documentation.